Call Girl Number in Panvel Mumbai📲 9833363713 💞 Full Night Enjoy
5-2. C3 glomerulonephritis and Dense Deposit Disease. Francesco Emma (eng)
1. C3 glomerulonephritis and Dense Deposit Disease
Francesco Emma
Division of Nephrology and Dialysis
Bambino Gesù Children’s Hospital, IRCCS
Rome, Italy
2. The area of complement….
Leslie M., Science 2012
3. MPGN – “classic classification”
MPGN Type I
Subendothelial deposits
West et al, J Pediatr 1965
MPGN Type II / DDD
Intramembranous deposits
Galle, Thesis 1962; Habib et al, Kidney Int 1975
MPGN Type III
Subendothelial and subepithelial deposits
Burkholder et al, Am J Pathol 1969
Anders et al, Virchows Arch A Pathol Anat Histol 1997
Strife et al, Clin Nephrol 1984
4. C3GN
19 patients with unusual glomerulonephritis and:
- C3NeF positivity (7), CFH (3), CFI (2) or MCP (1) mutations
- overt mesangial and epimembranous C3 deposits
- absence of dense intramembranous deposits
- no Ig deposition
5. Evidence for a role of complement in DDD/C3GN in humans
• Proteomic profile of microdissected glomeruli:
C3, C4, C5, C6, C7, C8, FHR1, FHR5….
• Very similar profile between DDD and C3GN
Sethi et al Kidney Int 2009; Sethi S et al Clin J Am Soc Nephrol 2011
6. Histology in DDD and C3GN
DDD
Mesangial proliferation
MPGN
Crescentic / Exudative GN
C3GN
45%
35%
10%
40%
55%
5%
Servais A, J Med Genet 2007
Walker PD et al, Modern Pathol 2007
Fakhouri F et al, Nature Rev Nephrol 2010
Sethi S, Kidney Int 2012
7. Glomerular lesions in DDD
MPGN
Mesangial proliferation
Crescentic
Diffuse endocapillary
proliferation
Walker PD et al, Modern Pathol 2007
8. The diagnosis of DDD requires electron microscopy
DDD
Walker PD et al, Modern Pathol 2007
C3GN
Sethi S et al, Clin J Am Soc Nephrol 2011
9. Glomerular lesions in C3GN
Mesangial proliferation
MPGN
Diffuse endocapillary
proliferation
Sethi S, Kidney International (2012) 82, 465–473
12. New classification based on the MPGN pattern
*
MPGN1
DDD
C3GN
Sethi S and Fervenza FC, Semin Nephrol 2011
Sethi S and Fervenza FC, NEJM 2012
*Servais et al, Kidney Int 2012; Dragon-Durey et al. JASN 2004;
Vaziri-Sani et al. Kidney Int 2006; Leroy V et al. Ped Nephrol 2011
13. MPGN1 can also be secondary to dysregulation
of the complement alternative pathway
Servais et al, Kidney Int 2012
14. A simplified view of the complement system
Zipfel and Skerka, Nat Rev Immunol 2009
18. The C3 convertase can be activated in the
fluid-phase or on cell surfaces
19. The C3 convertase can be activated in the
fluid-phase or on cell surfaces
Adapted from Rodríguez de Córdoba S et al., Biochem Biophys Acta, 2011
20. C3 mutations in DDD
• Mutation in the C3 gene (923ΔDG) which lacks 2 amino acids
• Generates an active C3-convertase that is:
- normally regulated by DAF on the surface of endothelial cells
- resistant to decay by factor H in the plasma
Conclusion:
fluid phase-restricted dysregulation of the AP
21. The C3 convertase can be activated in the
fluid-phase or on cell surfaces
C-terminal region
surface binding
(glycosaminoglycans/heparins)
Rodríguez de Córdoba S et al., Biochem Biophys Acta, 2011
22. CFH domain mutations in aHUS and DDD
C-terminal region
surface binding
(glycosaminoglycans/heparins)
Rodríguez de Córdoba S et al., Biochem Biophys Acta, 2011
23. The role of C3 vs. C5 in MPGN
Cfh-/- mice
Cfh-/- FHD16-20 mice
MPGN
aHUS
C3
Prevented if:
Worsen if:
Improved if:
C3
Cfi-/-
C5-/- or anti-C5
C3 activation
C5-/- or anti-C5
Dependent on C3>>C5
Dependent on C5
Rose et al, J Clin Invest, 2008
Pickering et al. Nat Genet 2002
Pickering et al. PNAS 2006
Goicoechea de Jorge, JASN 2011
28. DDD / C3GN: autoimmune forms
• C3 nephritic factor (C3NeF):
- IgG binding to neoepitope on alternative C3 convertase (C3bBb)
- Stabilizes C3bBb against intrinsic and extrinsic decay
- Present in all MPGN subtypes (DDD: 55% adults and 80% children)
- High degree of inter-/intraindividual variability – poor predictive value
Schwertz et al, Acta Paediatr 1986; Schwertz et al, Pediatr Allergy Immunol 2001
• CFH (mini-)antibody:
- Binds to CFH SCR3 and inhibits CFH cofactor activity
- Phenotype DDD
Meri et al, J Exp Med 1992; Jokiranta et al, J Immunol 1999
• CFB autoantibody:
- Binds Bb
- Similar effect as C3NeF
- Enhances C3 conversion
- Phenotype DDD
Strobel et al, Mol Immunol 2010
29. C3NeF: still poorly understood…
What epitopes do they bind and how tightly ?
Do they all stabilize the convertase to the same extent ?
Do they act on cell surface ?
Do differences correlate with the phenotype ?
Do they disappear spontaneously ?
30. DDD / C3GN: genetic forms
Courtesy of Christoph Licth
Gene /
Protein
Mutation / Variant
Function
CFH
Mutations:
- homo- / compound
heterozygous
- SCRs 1-4
(regulatory domain)
- Cys residues
(tertiary structure)
- Intact surface binding
- Reduced C3b binding
- Loss of CFH cofactor and
decay accelerating activity
DDD
C3GN
CFH
Polymorphisms:
- Y402H (SCR 7)
- Impaired C3b / heparin binding
- Impaired CFH cofactor activity
DDD
CNV:
- CFHR3-1 hybrid gene
- Not tested
- ?Dominant negative effect
C3GN
Malik, J Am Soc Nephrol 2012
CFHR5
CNV:
- Duplication within
CFHR5 exons 2/3
- Not tested
- ?Dominant negative effect
C3GN
Gale, The Lancet 2010
CFHR5
Polymorphisms
- Not tested
DDD
Abrera-Abeleda, J Med Genet 2006
Abrera-Abeleda, J Am Soc Nephrol 2011
C3
Mutations:
- Heterozygous deletion
- C3mut resistant to cleavage
by C3bBb
- C3mut convertase –
resistant to CFH inactivation
DDD
Martinez-Barricarte, J Clin Invest 2010
C3
Polymorphisms
- Not tested
DDD
Smith, J Am Soc Nephrol 2007
Abrera-Abeleda, J Am Soc Nephrol 2011
CFHR3-1
Phenotype Reference
Levy, Kidney Int 1986
Meri, J Exp Med 1992
Vogt, Pediatr Nephrol 1995
Ault, J Biol Chem 1997
Dragon-Durey, J Am Soc Nephrol 2004
Licht, Kidney Int 2006
Habbig, Kidney Int 2009
Hageman, Proc Nat Acad Sci 2005
Abrera-Abeleda, J Med Genet 2006
Abrera-Abeleda, J Am Soc Nephrol 2011
31. Treatment of DDD / C3GN
No established therapy
Some cases may spontaneously improve
Some patients have a relapsing course
Immune-suppressive drugs (PDN, CsA, MMF) may be beneficial in
some cases, in particular if evidence of renal inflammation:
- anecdotal reports and retrospective cohort studies
- generally partial responses
Anti-C5 may be beneficial in some, but not all patients
32. Treatment of DDD with eculizumab
NB: not all patients
respond so well
NB: expensive!
Vivarelli et al, New England J Med 2012